Loading...
Loading...
Cyberonics, Inc.
CYBX today announced that the AspireHC generator for use in vagus nerve stimulation therapy was approved by the United States Food and Drug Administration (FDA) for commercial release.
The AspireHC generator represents the fifth generation of VNS Therapy technology. This product incorporates greater functionality for the benefit of patients and their physicians, including longer battery life, improved electronics and simplified features for programming.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in